imatinib mesylate

Type: Keyphrase
Name: imatinib mesylate
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

Novartis Drags DRL to Court over Gleevec

HYDERABAD:  Basel-headquartered Novartis Pharmaceuticals Corporation and Novartis AG dragged city-based Dr Reddy's Laboratories Ltd (DRL) and its US subsidiary Dr Reddy's Laboratories Inc to the US court over alleged patent infringement.As per Novartis' ... [Published New Indian Express - Oct 21 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

Court Report - October 2014 #3

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases .Tris Pharma Inc. v. Actavis Laboratories FL Inc. et al.1:14-cv-01309; filed October 15, 2014 in the District Court of Delaware• Plaintiff:  Tris Pharma ... [Published JD Supra - Oct 20 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

USTR’s Investigations On IP Rights Against India: Is There A Tenable Case?

The views expressed in this column are solely those of the authors and are not associated with Intellectual Property Watch. IP-Watch expressly disclaims and refuses any responsibility or liability for the content, style or form of any posts made to this ... [Published Intellectual Property Watch - Oct 20 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Ebola Viral Infections Therapeutics Pipeline Review, H2 2014 Report - 23 Companies & 30+ Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/mzj43q/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the ... [Published Individual.com - Oct 16 2014]
First reported Oct 10 2014 - Updated Oct 11 2014 - 2 reports

Net hoax leads to clamour for cure-all cancer drug

CHENNAI: A misinformation campaign on the internet about a cancer drug has led to many confused patients from across the country calling up the Adyar Cancer Institute for help.Imatinib Mesylate — a drug for treatment of leukemia and originally known by ... [Published Times of India - Oct 11 2014]
First reported Oct 03 2014 - Updated Oct 03 2014 - 1 reports

Tackling the proliferation of patents

, which incorporated in section 3(d) specific standards to assess patent applications in the field of chemicals and pharmaceuticals.In a case brought by Novartis (a Swiss pharmaceutical company) against the rejection of its patent application relating ... [Published Third World Network - Oct 03 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

Crystalline form K of imatinib mesylate

Crystalline forms of imatinib mesylate (F, G, H, I and K) and their respective characterization are disclosed. ... [Published Free Patents Online - Sep 30 2014]
Entities: imatinib mesylate
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Regorafenib in Gastrointestinal Stromal Tumors

Agaimy, A., Wunsch, P., Hofstaedter, F., Blaszyk, H., Rümmele, P., Gaumann, A. et al . (2007) Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 31: 113–120.Corless, C., ... [Published General Medicine eJournal - Sep 29 2014]
First reported Sep 28 2014 - Updated Sep 29 2014 - 1 reports

India’s draft rules on patenting drugs draw mixed response

Mumbai: India’s latest draft rules on patenting drugs that say modifications of existing medicines can be patented only if they show increased therapeutic value has drawn sharp reaction from international pharma companies.In 2006, the Madras high court ... [Published Livemint.com - Sep 28 2014]
First reported Sep 24 2014 - Updated Sep 25 2014 - 2 reports

ESMO 2014 to Feature New Oncology Data from Across Bayer Franchise

WHIPPANY, N.J., Sept. 24, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that data from its oncology portfolio, including Stivarga(R) (regorafenib) tablets, NEXAVAR(R) (sorafenib) tablets and Xofigo(R) (radium Ra 223 dichloride) ... [Published Scottrade - Sep 24 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

A Differential Role for CD248 (Endosialin) in PDGF-Mediated Skeletal Muscle Angiogenesis

by Amy J. Naylor, Helen M. McGettrick, William D. Maynard, Philippa May, Francesca Barone, Adam P. Croft, Stuart Egginton, Christopher D. BuckleyCD248 (Endosialin) is a type 1 membrane protein involved in developmental and pathological angiogenesis through ... [Published Plosone.org - Sep 23 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

The Downfall of Pharmaceutical Innovation

REUTERS.COMIndia, the emerging pharmaceutical powerhouse of the developing world, has recently become a battleground between generic and private pharmaceutical companies as they pit public health interests against intellectual property rights. As demand ... [Published Georgetown University Hoya - Sep 15 2014]

Quotes

The complaints in these cases are substantially identical.  Infringement of U S Patent Nos. 6,894,051 ( "Crystal Modification of a N-phenyl-2-pyrimidineamine Derivative, Processes for Its Manufacture and Its Use" issued May 17, 2005) and RE43,932 ("Crystal Modification of a N-phenyl-2-pyrimidineamine Derivative, Processes for Its Manufacture and Its Use," issued...
...Blogs have also been spreading the rumour, adding to the confusion. "We get atat least 20 calls every day from across the country asking for the tablet."
Chain mails have been going around about how the Adyar Cancer Institute is providing 'Imatinib Mesylate' free of cost to cancer patients. "We get atat least 20 calls every day from across the country asking for the tablet. But the drug can only treat chronic myeloid leukemia and two other types of cancer. It is not effective for other types of cancer" says T G Sagar, director the institute
"Among other patterning functions, various Ephs and ephrins have been shown to play a role in vascular development. The de-regulated re-emergence of some ephrins and their receptors in adults also has been observed to contribute to tumor invasion, metastasis and neo-angiogenesis. For example, dominant-negative, soluble EphA2 or A3 proteins exhibit effects on ephrin-induced endothelial cell function in vitro, and tumor angiogenesis and progression in vivo (Nakamoto, et al., Microsc Res Tech 59:58-67, 2002; Brantley-Sieders, et al., Curr Pharm Des 10:3431-42, 2004; Brantley, et al. Oncogene 21:7011-26, 2002; Cheng, et al. Neoplasia 5:445-56, 2003; and Dobrzanski, et al. Cancer Res 64:910-9, 2004). Furthermore, Eph family members have been found to be over-expressed on tumor cells from a wide variety of human solid tumors (Brantley-Sieders, et al., Curr Pharm Des 10:3431-42, 2004; Marme, Ann Hematol 81 Suppl 2:S66, 2002; and Booth, et al., Nat Med 8:1360-1, 2002)."

More Content

All (25) | News (22) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
Novartis Drags DRL to Court over Gleevec [Published New Indian Express - Oct 21 2014]
Court Report - October 2014 #3 [Published JD Supra - Oct 20 2014]
USTR’s Investigations On IP Rights Against Indi... [Published Intellectual Property Watch - Oct 20 2014]
Ebola Viral Infections Therapeutics Pipeline Re... [Published Individual.com - Oct 16 2014]
Spondyloarthritis Unifying Concepts to Improved... [Published General Medicine eJournal - Oct 15 2014]
Net hoax leads to clamour for cure-all cancer drug [Published Times of India - Oct 11 2014]
Patients clamour for cure-all cancer ‘wonder’ d... [Published Times of India - Oct 10 2014]
Tackling the proliferation of patents [Published Third World Network - Oct 03 2014]
Crystalline form K of imatinib mesylate [Published Free Patents Online - Sep 30 2014]
Patient access to orphan drugs faces new set of... [Published Formulary Journal - Sep 29 2014]
Regorafenib in Gastrointestinal Stromal Tumors [Published General Medicine eJournal - Sep 29 2014]
India’s draft rules on patenting drugs draw mix... [Published Livemint.com - Sep 28 2014]
KaloBios Pharmaceuticals : Patent Issued for Tr... [Published 4 Traders - Sep 24 2014]
ESMO 2014 to Feature New Oncology Data from Acr... [Published Scottrade - Sep 24 2014]
ESMO 2014 to Feature New Oncology Data from Acr... [Published TickerTech.com - Sep 24 2014]
A Differential Role for CD248 (Endosialin) in P... [Published Plosone.org - Sep 23 2014]
The Downfall of Pharmaceutical Innovation [Published Georgetown University Hoya - Sep 15 2014]
Methods and compositions for modulation of bloo... [Published PharmCast - Jul 17 2014]
[Comment] A modest but meaningful decision for ... [Published The Lancet online - Jun 27 2014]
GLEEVEC (Imatinib Mesylate) Tablet [Novartis Ph... [Published DailyMed Drug Label Updates for the last seven ... - Jun 02 2014]
Novartis agrees Gleevec patent deal [Published BioPortfolio - May 19 2014]
Sun, Novartis settle dispute [Published Calcutta Telegraph - May 15 2014]
Antibody-based arrays for detecting multiple si... [Published PharmCast - Mar 12 2014]
Methods and compositions for targeting agents i... [Published PharmCast - Jan 05 2014]
Fact Sheet for SMS Pharmaceuticals Limited [Published Able2Act - May 06 2008]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
[Comment] A modest but meaningful decision for ... [Published The Lancet online - Jun 27 2014]
On April 1, 2013, the Indian Supreme Court released its long-awaited decision on Novartis AG v Union of India & Others, better known as the Glivec (Gleevec in the USA; imatinib mesylate) patent case. Although neither the resounding victory for access ...
GLEEVEC (Imatinib Mesylate) Tablet [Novartis Ph... [Published DailyMed Drug Label Updates for the last seven ... - Jun 02 2014]
Updated Date: May 29, 2014 EST ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.